Last updated: February 17, 2026
Overview
NDC 64980-0503 corresponds to the Humira Pen, a biologic medication with the active ingredient adalimumab. It is indicated for multiple autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. Humira remains one of the most prescribed biologics worldwide.
Market Landscape
Humira's global sales peaked at approximately $21 billion in 2022, according to IQVIA data. Despite biosimilar entry in certain markets, it continues commanding significant market share due to its established efficacy and broad label. The drug's patent expirations range across regions, with the U.S. patent expiry occurring in 2023, opening opportunities for biosimilar competitors.
Key Competitors
- Biosimilars in the U.S.: Amgen’s Amjevita (adalimumab-atto), Samsung Bioepis/Biogen’s Hadlima, and Pfizer’s Cyramza are among approved biosimilars.
- Market Dynamics: Biosimilar adoption remains slow in the U.S. due to supply chain, payer preference, and clinician inertia. In Europe, biosimilars have gained a stronger foothold, reducing price points by up to 30-50%.
Pricing Trends
- Brand Price Point: The list price for the Humira Pen (40 mg) is approximately $6,000—$6,400 per injection, or around $40,000 - $45,000 per month.
- Post-Patent Biosimilar Prices: Biosimilars typically launch at a 20-30% discount to the originator. In the U.S., prices for biosimilars have ranged from $3,000 to $4,500 per dose. Commercial rebates and discounts further reduce the net price paid by payers.
Historical Price Movements
- Since 2016, drug list prices increased annually by 9%-12%. The entry of biosimilars in Europe in 2018 led to approximately 30% price reductions.
- The U.S. market generally lags behind Europe in biosimilar adoption, with actual net prices often 20%-50% lower due to rebates and negotiations.
Resilience Factors
- The drug's broad label and chronic use model sustain high revenue.
- Payer resistance to biosimilar substitution limits price erosion.
- Manufacturing complexities and patent litigations affect biosimilar market penetration and pricing.
| Price Projections (2023-2027) |
Year |
Estimated List Price (per injection) |
Estimated Net Price (per injection) |
Comments |
| 2023 |
$6,200 |
$4,000 - $4,500 |
Post-patent expiration, biosimilars entering markets; pricing pressure begins |
| 2024 |
$6,100 |
$3,800 - $4,200 |
Market stabilizes; biosimilar uptake steady, discounts persist |
| 2025 |
$6,000 |
$3,500 - $4,000 |
Increased biosimilar competition reduces list prices further; rebates impact net prices |
| 2026 |
$5,900 |
$3,300 - $3,800 |
Payer negotiations intensify; biosimilar market share expands |
| 2027 |
$5,800 |
$3,000 - $3,500 |
Long-term price stabilization; biosimilar adoption influences pricing structure |
Assumptions
- Biosimilar market penetration increases by an estimated 20-30% annually in the U.S.
- No significant new indications or formulation changes impact pricing.
- Regulatory and patent litigation outcomes remain consistent with current trends.
Implications for Stakeholders
- Biotech/Pharma Companies: Biosimilar entrants will pressure prices but may face delays due to market, regulatory, and legal barriers.
- Payers: Seek greater discounts and rebates; biosimilar substitution policies influence net prices.
- Providers: Given the high costs, physicians are motivated to switch to biosimilars where rebate and formulary policies support such moves.
Summary
Humira (NDC 64980-0503) displays a resilient revenue profile due to its broad label and established market presence. However, patent expirations and biosimilar competition are expected to reduce list and net prices over the next five years. Price declines are initially modest but may accelerate as biosimilar market share expands and payer negotiations tighten.
Key Takeaways
- Humira's list price approximately $6,200 per injection post-2023 patent expiry.
- Biosimilars entered the market at a 20-30% discount, with net prices dropping further due to rebates.
- Price erosion projected to be 10-20% annually for the next five years.
- Biosimilar adoption remains crucial in shaping price trends.
- Payer policies heavily influence net pricing and market share.
FAQs
1. How does biosimilar entry affect Humira's pricing?
Biosimilars usually launch at a 20-30% discount on list prices, forcing originator prices downward and increasing market competition. Payer negotiations and rebate structures further influence net prices.
2. What are the key risks to price stability?
Legal disputes over patents, delayed biosimilar approval, and slow adoption by prescribers can slow price declines. Changes in formulary policies may also impact pricing dynamics.
3. How do regional differences influence pricing?
Europe has experienced faster biosimilar uptake and more aggressive price reductions (~50%), compared to slower adoption in the U.S., where rebates and payer resistance slow price erosion.
4. What is the timeline for price decline?
Significant price reductions are projected between 2023 and 2025, stabilizing at around 10-15% annual declines through 2027.
5. How should investors or pharmaceutical companies prepare?
Focus on biosimilar development, monitor patent litigations, engage with payers for formulary positioning, and optimize rebate strategies to mitigate revenue losses.
